Researchers at Yale have found that injury to endothelial cells — the cells lining blood vessels — may be a key driver of COVID-19 severity and death. The findings, published in the June 30 edition of The Lancet Haematology, may help to explain the mysterious blood clotting seen in some patients with COVID-19, a condition associated with the most severe cases and death. The discovery suggests that doctors could both test patients for endothelial cell injury, known as endotheliopathy, and mitigate it with drugs to improve patient outcomes.
The researchers studied 68 patients admitted to Yale New Haven Hospital with COVID-19, including 48 critically ill patients, 20 non-critically ill patients, and 13 non-hospitalized healthy controls, looking at markers for endothelial cell (EC) injury and comparing those to illness severity and survival. They found that markers for EC injury were significantly elevated in critically ill patients and were above the normal range in 80% of non-critically ill patients. Moreover, the elevated markers were significantly associated with lower rates of hospital discharge and higher likelihood of death.
Previous studies had determined that patients with COVID-19 are at high risk for blood clots and strokes — with one Dutch study finding that 31% of ICU patients who were already on preventive doses of blood thinners had blood clot complications, a number it called “remarkably high.” In New York, doctors at Mt. Sinai have reported a high number of young stroke patients who tested positive for COVID-19. Autopsy reports from two dozen Black patients who died from COVID-19 at LSU Health found that all had blood clots in the lungs.
“Recognizing this increase in blood clotting risk, at the time that we began our study, a couple small autopsy series had found evidence of endothelial cell infection or inflammation in the lungs,” said senior author Dr. Alfred Lee, associate professor of medicine (hematology) and director of the hematology/oncology fellowship program at Yale. “Our study is the first to measure specific markers of endothelial injury in the blood and demonstrate that endotheliopathy is common in COVID-19, especially when patients are critically ill.”
Co-senior author Dr. Hyung Chun, associate professor and director of translational research in the Yale Pulmonary Vascular Disease Program, said doctors treating patients with COVID-19 are not routinely testing for injury to the endothelial cells, but that these findings indicate it could be beneficial to patients to add this to the standard of care.
“We are tackling the disease from two fronts,” said Chun. “First, we are trying to better understand what is happening to the endothelial cells as the disease progresses and finding circulating biomarkers that might be predictive of someone becoming very ill.” Second, he said, is the therapeutic perspective. “Once we have a clearer understanding of the disease mechanisms, we can consider evaluating drugs that target these mechanisms which may already be approved for other indications.”
Already, said Lee, any hospitalized patients with COVID-19 are given at least a low dose of blood thinner. Their new data, said Lee, suggest that other drug interventions that protect the endothelial cells may afford further benefit in treatment of patients with COVID-19.
The researchers have received approval to begin enrolling patients in a clinical trial at Yale to further study the connection between inflammation, blood vessel injury, and COVID-19 outcomes.
Three Yale trainees led the study: Dr. George Goshua and Dr. Alexander Pine, clinical fellows in the section of hematology, and Matt Meizlish, an M.D./Ph.D. student, who are co-first authors of the manuscript. C. Hong Chang and Hanming Zhang, both postdoctoral fellows in the section of cardiology, along with other faculty and staff in the benign hematology program and in the department of laboratory medicine at Yale, also contributed.